Ocata Therapeutics Inc fka OCAT

[farviewhill]

My 2 cents, also echoed by so few.
Ocata does not anymore even begin to be a 'sound' biotech risk investment, especially at this share price, until:
-a sensible, non dilutive financing is secured and announced.
-a meaningfully designed phase 2 commences; and
-confirming safety and efficacy data starts to emerge in phase 2, but
recognizing that huge investing caution remains of utmost importance
given the historically torturous remaining fda requirements that
historically leaves even the most exciting biotechs unfortunately to
non-approval and none were in the new stem cell science, to boot
sadly so.

None of these thoughts are to negate hope for Ocata's success, but imo, speak only and directly to the realities of Ocata strictly as an investment at this time.